Can a lower dose of a myeloma drug keep the disease in check with fewer side effects?

This trial asks whether a reduced dose of belantamab mafodotin, combined with pomalidomide and dexamethasone, can control relapsed or refractory multiple myeloma as effectively as the standard dose while causing fewer side effects. Adults with this blood cancer who have had at least one prior therapy are randomly assigned to receive either the reduced or standard dose. The study tracks treatment response, minimal residual disease (a sensitive measure of remaining cancer cells), and side effects, especially eye-related toxicity.